123 Street, NYC, US 0123456789 [email protected]

爱上海,上海419论坛,上海龙凤419 - Powered by Makenna Bufu!


first_img“Every piece of equipment, including Wi-Fi and computers, was paid for by the campaign, and no White House staff is involved,” he added. “The arrangement has been approved by White House counsel.”Previous administrations have monitored elections from the White House, although some of have been mindful of avoiding having campaign staff involved.For instance, according to a person involved in the operation, when former President George W. Bush ran for re-election in 2004, his team had a setup in the White House residence with a screen allowing officials there to monitor campaign data. It was approved by the White House Counsel’s Office.- Advertisement – – Advertisement – President Trump’s campaign has set up two election night “war rooms” in the White House complex, raising questions anew about the intermingling of the governmental and the political in the Trump administration.One war room is in the Eisenhower Executive Office Building, which is adjacent to the White House, campaign and White House officials confirmed. White House officials also said there is a separate, smaller room in the White House building.- Advertisement – Trump campaign spokesman Tim Murtaugh said in a statement that the war room “needed to be in close proximity to the president and there is no expense whatsoever to American taxpayers for the use of a room in the EEOB, where events like prayer services and receptions for outside groups frequently occur.”- Advertisement –center_img But in that case, campaign staff were not present, and officials involved had to demonstrate they’d worked a certain number of government hours in order to participate, the person involved said. The use of government property for political purposes has been a recurring practice of the Trump administration over the past year. Mr. Trump held the final night of the Republican National Convention on the South Lawn of the White House at the end of August, after plans were repeatedly altered because of the coronavirus pandemic.In the final months of the race for president, Mr. Trump has also increasingly relied on political appointees and government agencies to bolster his re-election campaign.last_img read more


first_imgOn Wednesday, Feb. 5, Rohit Varma, M.D., M.P.H. was named as the chair of the Department of Ophthalmology and the director of the USC Eye Institute. Varma was previously a professor at the Keck School of USC, as well as a director of the clinical trials unit, the glaucoma service, and ocular epidemiology.Rohit Varma, M.D., M.P.H. Photo courtesy of Van Urfalian.Varma will also be an associate dean with the Keck School of Medicine. He is known for his research in a multitude of eye studies, including the Los Angeles Latino Eye Study (LALES) and the African-American Eye Disease Study. Varma is also known for his ability to work with new imaging techniques used in the treatment and detection of glaucoma.Varma has worked on developing imagining techniques to help with the early diagnosis of glaucoma caused by optic nerve damage. Varma was also a pioneer in developing implantable intraocular pressure (IOP) sensors and drainage devices used to control and possibly cure glaucoma. According to the Glaucoma Research Foundation, glaucoma one of the leading cause of blindness.In addition, Varma has been published in more than 219 ophthalmic journals, and was a co-wrote Essentials of Eye Care: The Johns Hopkins Wilmer Handbook and The Optic Nerve in Glaucoma. He has been awarded the Glaucoma Research Foundation President’s Award and he was named a Sybil B. Harrington Scholar.Varma completed his residency at Johns Hopkins Hospital in Baltimore after receiving his medical degree from the University of Delhi in India. He also has a master’s degree in Public Health from Johns Hopkins University. Varma also finished two glaucoma fellowships, one from the Wills Eye Hospital and one from USC.Mark S. Humayun, M.D., Ph.D. will continue as co-director for the USC Eye Institute, as well as the director of the Institute for Biomedical Therapeutics.last_img read more